The Head of the Department of Chemistry, Professor Dr. Muhammad Nazem Bahgat, obtained a patent from the Central Organization for Standardization and Quality Control to enable him to prepare a new nanocomposite drug (nanopolymer – methotrexate) and study its biological effectiveness against breast cancer, develop an effective drug delivery system for clinical application against Breast cancers. The patent included the preparation of a new co-nanopolymer from phthalic anhydride and glycerol in the first step, whereby a nanopolymer is formed. The patent also consisted of two hydroxyl groups and two free, non-alloyed carboxyl groups, which play a major role in the swelling process. In the second step, the drug molecules were linked to the nanopolymer in ratios (1:1 mole) of the polymer and the drug, respectively, through the amide bond formation reaction using… Microwave using dimethylformamide (DMF) as a solvent and DDC as a catalyst, and the release rate of the drug loaded on the nanopolymer was measured in two acidic and basic media (pH 2.2 and pH 8.0) and at a temperature of 37 degrees Celsius. The patent aimed to ensure that the basal medium was the best in releasing the drug in hours and days, and the nature of the interactions between the drug loaded on the polymer and the protein that causes the growth and spread of breast cancer (Estrogen Receptor Alfa) was studied by using the computer program (AutoDock Vina and PyMol). The amino acids that make up the protein and that attract the drug were also identified.
